This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-10. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
=== 1918 influenza pandemic === The influenza pandemic of 1918 placed a sever strain on Oregon’s hospitals and public health infrastructure. At the time, the viral cause of influenza had not yet been identified, and many physicians believed that the high mortality rate resulted from secondary bacterial infections. In response, the Oregon State Board of Health supplied Lawrence’s laboratory with an infected tissue sample obtained from a navy yard in Bremerton, Washington. Lawrence isolated hemolytic streptococcus from patient samples and developed a vaccine targeting this bacterium, which was associated with secondary pneumonia in influenza patients. Although described at the time as an influenza vaccine, the preparation was designed to combat bacterial infections that frequently followed influenza rather than the virus itself. The vaccines produced in her laboratory were distributed to physicians throughout Oregon as part of broader public health efforts. Her work received national recognition, and she was later honored by President Woodrow Wilson for her contributions.
Analytical application of the radiotracer method is a forerunner of isotope dilution. This method was developed in the early 20th century by George de Hevesy for which he was awarded the Nobel Prize in Chemistry for 1943. An early application of isotope dilution in the form of radiotracer method was determination of the solubility of lead sulphide and lead chromate in 1913 by George de Hevesy and Friedrich Adolf Paneth. In the 1930s, US biochemist David Rittenberg pioneered the use of isotope dilution in biochemistry enabling detailed studies of cell metabolism.
=== Competition === In an interview in Swedish business monthly Affärsvärlden in 2006, then Tetra Pak CEO Dennis Jönsson stated that Tetra Pak's main competitor was Swiss manufacturer SIG Combibloc, adding that Tetra Pak's main competition generally no longer comes from companies producing similar packaging but from industries and companies producing other types of packaging with a lower cost of production, like the PET bottle. Jönsson perceived the PET bottle as Tetra Pak's biggest threat in the European market at the time. The Norwegian company Elopak/Pure-Pak produces similar style carton packages and has historically been Tetra Pak's principal competitor. The Chinese packaging company Greatview has begun challenging Tetra Pak, both in the Chinese market and in Europe.
Following Viserys' death, this friction exploded into the Targaryen civil war known as the Dance of the Dragons, with the blacks supporting Rhaenyra's claim to the throne and the greens supporting Aegon II's claim. Viserys' official character description depicts him as a "level-headed decision maker" who presided over a peaceful, but challenging reign. Both the character of Viserys and Considine's performance received universal acclaim, many deeming him the best character in the show and one of the best characters in the Game of Thrones universe, as well as an improvement on his book counterpart.
Sources: en.wikipedia.org
== Overview == Trails is a series of role-playing video games by Nihon Falcom set in a science fantasy universe. It began as the sixth entry in Falcom's The Legend of Heroes franchise with the release of The Legend of Heroes VI: Trails in the Sky in 2004. Despite that, it had no narrative connection with prior Legend of Heroes games and is considered its own distinct franchise. The Trails games are set within a few years of each other and follow an overarching narrative, with the events of a few entries crossing over into another. The series was conceived by Falcom to have the most ambitious story in video games, with company president and series producer Toshihiro Kondo considering it to be his life's work. The games are made using a proprietary game engine known as the Falcom Developer Kit (FDK), with the exception being Sony's PhyreEngine used for the Trails of Cold Steel games and Trails into Reverie. The series is heavily influenced by anime and features several archetypes and tropes common to it. Trails is set across several locations on the continent of Zemuria, such as the Liberl Kingdom, the city-state of Crossbell, the Erebonian Empire, and the Calvard Republic, among others. Zemuria is home to several groups, factions, and organizations, such as the Bracer's Guild, the Septian Church, the secret society of Ouroboros, mercenary groups known as Jaegers, and several more. The series is set half a century after the discovery of orbal energy, an analog to electric power.
Livagen is a tetrapeptide with the sequence KEDA or Lys-Glu-Asp-Ala. It is one of a number of small peptides developed in Russia in the late 1990s and early 2000s which have antiinflammatory and purported anti-aging effects, and are now widely sold over the internet as anti-aging products though with relatively limited evidence to support these claims.
Precursors to chemistry Alchemy (outline) History of alchemy History of the branches of chemistry History of analytical chemistry – history of the study of separation, identification, and quantification of the chemical components of natural and artificial materials. History of cosmochemistry – history of the study of the chemical composition of matter in the universe and the processes that led to those compositions History of atmospheric chemistry – history of the branch of atmospheric science in which the chemistry of the Earth's atmosphere and that of other planets is studied. It is a multidisciplinary field of research and draws on environmental chemistry, physics, meteorology, computer modeling, oceanography, geology and volcanology and other disciplines History of biochemistry – history of the study of chemical processes in living organisms, including, but not limited to, living matter. Biochemistry governs all living organisms and living processes. History of agrochemistry – history of the study of both chemistry and biochemistry which are important in agricultural production, the processing of raw products into foods and beverages, and in environmental monitoring and remediation. History of bioinorganic chemistry – history of the examination of the role of metals in biology. History of bioorganic chemistry – history of the rapidly growing scientific discipline that combines organic chemistry and biochemistry. History of biophysical chemistry – history of the new branch of chemistry that covers a broad spectrum of research activities involving biological systems.
=== Newborn screening === Several countries test all newborns for SCID as a part of routine newborn screening. A measure using real-time quantitative PCR of the blood concentration of T-cell receptor excision circles (TRECs), which are reduced in SCID, is the method used to screen all U.S. newborns for SCID. As of September 2022, the known percentage of newborns screened has increased throughout the world with 100% in the United States, 100% in Australia, 78% in Europe, 32% in Latin America, 26% in the Middle East and North Africa, 13% in Asia-Pacific, and 0% in Central America. The introduction of newborn screenings and genetic testing in many countries has allowed early detection and treatment before the development of severe infections, which progressively improved the five-year survival rate for newborns with SCID to around 90%.
Neural connections are constantly changing within the nervous system. Synaptic connections that are used more often are kept intact and promoted, while synaptic connections that are rarely used are subject to degradation. Elevated levels of synaptic connection loss and degradation of neurons are linked to neurodegenerative diseases. More recently, ferroptosis has been linked to diverse brain diseases, in particular, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. Two new studies show that ferroptosis contributes to neuronal death after intracerebral hemorrhage. Neurons that are degraded through ferroptosis release lipid metabolites from inside the cell body. The lipid metabolites are harmful to surrounding neurons, causing inflammation in the brain. Inflammation is a pathological feature of Alzheimer's disease and intracerebral hemorrhage. Recent studies have suggested that ferroptosis contributes to neuronal cell death after traumatic brain injury. Hypoxic brain injury in resuscitated patients shows retrospective evidence of ferroptosis. Additionally there is evidence that the prion protein and pathogenic prions PrPSc contribute to ferroptosis sensitivity in the brain, a condition that is enhanced by RAC3 expression.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.